An Exciting New Treatment Option
Please check this section frequently for updates on news announcements, industry events, and for our latest media resources.
13th EURETINA Congress
September 11-14, 2014 | London, United Kingdom
Visit the Oraya Therapy Booth C11
See the IRay and experience a demonstration
Latest Press Releases
Wednesday, August 20, 2014 | Sheffield Teaching Hospitals NHS Foundation Trust has become the first NHS hospital in the UK to start offering appropriate patients a new non-invasive treatment for wet age-related macular degeneration (wet AMD)…More >
Tuesday, August 5, 2014 | Oraya® Therapeutics, Inc. announced today that they have been awarded a $215,000 Small Business Technology Transfer Grant from the National Institutes of Health to investigate how Oraya Therapy, a low voltage stereotactic radiotherapy, and gold nanoparticles can further enhance the treatment of wet age-related macular degeneration (Wet AMD)…More >
Tuesday, July 22, 2014 | Oraya® Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany…More >
Friday, November 15, 2013 | Oraya® Therapeutics, Inc. announced today that initial three-year safety follow-up data from its INTREPID study of Oraya Therapy™ stereotactic radiotherapy for the treatment of wet age-related macular degeneration (AMD) were presented for the first time today during the America Academy of Ophthalmology’s (AAO) annual meeting in New Orleans…More >
Tuesday, November 12, 2013 | Oraya Therapeutics, Inc. and OnCore Manufacturing LLC announced today the production of the first commercial unit in the United States of the IRay® Radiotherapy System for the treatment of wet age-related macular degeneration (AMD)…More >
Wednesday, September 25, 2013 | Oraya Therapeutics, Inc. announced today the two-year results of its INTREPID study of Oraya Therapy™ Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD)…More >
Wednesday, August 14, 2013 | Oraya Therapeutics, Inc. announced today that the Oraya Therapy™ Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD) is now available at Optegra Manchester Eye Hospital…More >
Thursday, April 18, 2013 | Oraya Therapeutics, Inc. today announced that results of its INTREPID study evaluating the safety and efficacy of Oraya Therapy™ Stereotactic Radiotherapy…More >
Thursday, April 4, 2013 | New Therapy for Wet AMD Introduced in Switzerland by Oraya® Therapeutics and EyeRAD…More >
November 7, 2013 | San Francisco Business Times
East Bay connection: Oraya, OnCore partnership a lesson in medical manufacturing.
November 4, 2013 | MedCity News
Healthcare startup with noninvasive, one-time wet AMD treatments touts two years of success.
October 2013 | Retina Today
Intrepid Study Demonstrates 2-Year Safety, Efficacy of Oraya Therapy.
October 2, 2013 | eyewireTV Weekly
Two-year results of Oraya Therapeutics’ INTREPID study are presented, showing that radiation therapy for wet AMD is safe and effective.
September 25, 2013 | eyewireToday
Oraya Therapeutics INTREPID Study Demonstrates 2-year Safety and Effectiveness of Non-invasive Therapy for Wet AMD.
September 2013 | EUROTIMES Seminar Supplement 12th EURETINA Congress
Oraya Therapy – A Significant Advance in the Treatment of Wet AMD
September 30, 2013 | CHOICE
X-ray Aid For Eyes
September 30, 2013 | Readers Digest
This Won’t Hurt A Bit
June/July, 2013 | Vision Magazine, Issue 60
Radiotherapy breakthrough to treat wet AMD
Presented at 2012 AAO-APAO Joint Meeting
IRay Plus Anti-VEGF Treatment for Patients with Wet Age-Related Macular Degeneration: The INTREPID Trial of Stereotactic Radiotherapy for Choroidal Neovascularization in AMD
Peter K. Kaiser, MD View Video >